COMPARISON OF EFFECTS WHEN SWITCHING LONG-ACTING INSULIN: RANDOMISED CROSSOVER STUDY
- SOICHI Takeishi, Japan
- SOICHI Takeishi, Japan
- Hiroki Tsuboi, Japan
Abstract
Background and Aims
We investigated glycaemic variability from one day before to 6 days after switching in patients treated with long-acting insulin.
Methods
This study was conducted during hospitalization. 20 type 2 diabetic patients on basal insulin therapy were randomly allocated to two groups. In Group1, fasting blood glucose level was stabilized (not exceeding 180 mg/dL) using insulin glargine 300 U/mL (Glargine300); Glargine300 was continued for 6 days with the same dose; a continuous glucose monitoring device (FreeStyle Libre Pro) was worn on the fifth day of Glargine300 administration of the same dose (=attaching day:Day1); next, Glargine300 was switched to insulin degludec (Degludec) on Day3 with the same dose, and then Degludec was continued for 6 days with the same dose; Degludec was then switched to Glargine300 on Day9 with the same dose, and then Glargine300 was continued for 6 days with the same dose. Long-acting insulin was injected at 08:00. Test meals were given. In Group2, patients were administered in the order of Degludec, Glargine300, and Degludec, following the same regimen as Group1. Evaluation duration was from 24-h before to 144-h after switching.
Results
Mean of daily difference (MODD) between day2 and day3 (switch day:day1) was significantly lower in patients who switched from Glargine300 to Degludec (pGtoD) than in patients who switched from Degludec to Glargine300 (pDtoG). The others endpoints weren’t significantly different between pGtoD and pDtoG (table).
Conclusions
Day-to-day glycaemic variability between day2 and day3 was lower in pGtoD than in pDtoG.